Summary of Veru Inc. Q3 2026 Earnings Call

1Key Financial Results and Metrics:

Net Loss: $7 million, or $0.30 per diluted share, improved from a net loss of $7.3 million, or $0.50 per diluted share in the prior quarter.

Research and Development Costs: Increased to $4.4 million from $3 million, primarily due to the ongoing Phase IIb PLATEAU clinical study.

General and Administrative Expenses: Decreased to $3.4 million from $5 million, attributed to lower share-based compensation and consulting expenses.

Cash Position: Cash, cash equivalents, and restricted cash totaled $23.9 million as of June 30, 2026, up from $15.8 million as of September 30, 2025.

Net Working Capital: Increased to $21.1 million from $11.1 million.

2Strategic Updates and Business Highlights:

Product Development: Focus on two key assets: enobosarm (for obesity treatment) and sabizabulin (anti-inflammatory agent). Enobosarm is being developed to enhance weight loss while preserving lean mass in older patients with sarcopenic obesity.

Clinical Trials:

Completed enrollment in the Phase IIb PLATEAU clinical trial with 239 patients, aiming to assess the efficacy of enobosarm in conjunction with semaglutide.

The interim analysis is expected in Q1 2027.

Patent Developments: Received a notice of allowance for a key patent related to enobosarm's use in combination with weight loss drugs, extending potential market exclusivity until at least 2044.

Partnership: Entered a supply agreement with Novo Nordisk for semaglutide for the PLATEAU study, enhancing collaboration in obesity treatment.

3Forward Guidance and Outlook:

Clinical Milestones: Anticipating results from the interim analysis of the PLATEAU trial in early 2027, with final data expected by Q4 2027.

Market Potential: Targeting a significant market of older patients with obesity, particularly as Medicare expands coverage for weight loss drugs.

4Bad News, Challenges, or Points of Concern:

Operating Losses: Continued net losses and negative cash flow from operations indicate ongoing financial challenges.

Market Competition: Facing competition from established players like Eli Lilly and Novo Nordisk, which have already demonstrated significant weight loss results with their products.

Regulatory Risks: The success of enobosarm and its market acceptance depend on regulatory approvals and the ability to demonstrate significant clinical benefits over existing therapies.

5Notable Q&A Insights:

Intellectual Property Concerns: Discussion on the significance of the new patent for enobosarm in combination with GLP-1 drugs, with a focus on broadening patent protection as the GLP-1 class evolves.

Market Strategy: Emphasis on the need to define a specific patient population for enobosarm, particularly older patients at risk of muscle loss, aligning with regulatory expectations for targeted therapies.

Commercial Potential: The management highlighted the growing recognition of the issues faced by older patients on GLP-1s and the potential for enobosarm to fill this gap, supported by Medicare's evolving coverage policies. Overall, Veru Inc. is making strategic progress in its clinical development and patent portfolio, although it faces ongoing financial losses and competitive pressures in the biopharmaceutical market.